Skip to main content
. 2016 Dec 9;139:1–12. doi: 10.1016/j.antiviral.2016.12.007

Fig. 3.

Fig. 3

Histological slides show representative lung pathology. (a). SARS-CoV-infected, Hiltonol®-treated lung with small numbers of neutrophils within groups of alveoli and moderate rims of lymphocytes surrounding scattered vessels. (b). SARS-CoV-infected, Hiltonol®-treated lung with moderate rims of lymphocytes surrounding scattered vessels. (c). SARS-CoV-infected, Hiltonol®-treated lung with clusters of alveolar macrophages and neutrophils filled small groups of alveoli. (d). Un-infected, Hiltonol®-treated lung with moderate rims of lymphocytes surround scattered vessels. (e). SARS-CoV-infected, Ampligen®-treated lung with approximately 80% airspaces contain erythrocytes. (f). SARS-CoV-infected, PSS-treated lung with small number of alveolar macrophages and fewer neutrophils within alveoli.